Considerations for using ACEIs and ARBs in COVID-19 patients SARS-CoV-2 enters human cells by hijacking ACE-2 receptors. Some studies indicate encouraging role of ACEIs and ARBs in COVID-19 patients. However, there is uncertainty related to continuing or stopping these drugs. According to a study, there is no evidence that indicates benefit of switching from ACEIs/ARBs to antihypertensive medicines. A study in Nature Cardiology says “Whether patients with COVID-19 and hypertension who are taking [an] ACE inhibitor/ARB should switch to another antihypertensive drug remains controversial, and further evidence is required”. Moreover, none of the drug regulatory bodies across the world recommend switching from antihypertensive medicines to ACEIs/ARBs and vice versa. According to European Medicines agency, there is no evidence that indicates worsening of COVID-19 infection from ACEIs/ARBS. Therefore, COVID-19 patients must continue taking these medicines.